These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 24148119)
1. [Anti-viral treatment: pro or cons type I IFN?]. Whitehead P; Drouet B; Zagury D; Bensussan A Med Sci (Paris); 2013 Oct; 29(10):836-9. PubMed ID: 24148119 [No Abstract] [Full Text] [Related]
2. [The first answer to viral infections: type I interferon]. Pichlmair A; Pollak M; Bergthaler A Berl Munch Tierarztl Wochenschr; 2004; 117(7-8):252-65. PubMed ID: 15298051 [TBL] [Abstract][Full Text] [Related]
3. Targeting of type I interferon in systemic autoimmune diseases. Crow MK; Olferiev M; Kirou KA Transl Res; 2015 Feb; 165(2):296-305. PubMed ID: 25468480 [TBL] [Abstract][Full Text] [Related]
4. Overview of the biology of type I interferons. Kalliolias GD; Ivashkiv LB Arthritis Res Ther; 2010; 12 Suppl 1(Suppl 1):S1. PubMed ID: 20392288 [TBL] [Abstract][Full Text] [Related]
5. [Interferon therapy in chronic viral hepatitis; an autoimmunity dilemma]. Gutkowski K; Gutkowska D; Bilkiewicz T Przegl Lek; 2007; 64(3):148-52. PubMed ID: 17941466 [TBL] [Abstract][Full Text] [Related]
6. Type I interferon and autoimmune disease. Crow MK Autoimmunity; 2003 Dec; 36(8):445-6. PubMed ID: 14984020 [No Abstract] [Full Text] [Related]
7. The type I interferon system in the development of lupus. Rönnblom L; Alm GV; Eloranta ML Semin Immunol; 2011 Apr; 23(2):113-21. PubMed ID: 21292501 [TBL] [Abstract][Full Text] [Related]
8. Interferon regulatory factors: beyond the antiviral response and their link to the development of autoimmune pathology. Santana-de Anda K; Gómez-Martín D; Díaz-Zamudio M; Alcocer-Varela J Autoimmun Rev; 2011 Dec; 11(2):98-103. PubMed ID: 21872684 [TBL] [Abstract][Full Text] [Related]
9. Type I Interferon and the Spectrum of Susceptibility to Viral Infection and Autoimmune Disease: A Shared Genomic Signature. Sugrue JA; Bourke NM; O'Farrelly C Front Immunol; 2021; 12():757249. PubMed ID: 34917078 [TBL] [Abstract][Full Text] [Related]
10. Autoimmune manifestations during interferon therapy in patients with chronic hepatitis C: the hepatologist's view. Pellicano R; Smedile A; Peyre S; Astegiano M; Saracco G; Bonardi R; Rizzetto M Minerva Gastroenterol Dietol; 2005 Mar; 51(1):55-61. PubMed ID: 15756146 [TBL] [Abstract][Full Text] [Related]
11. Type I Interferon in Chronic Virus Infection and Cancer. Snell LM; McGaha TL; Brooks DG Trends Immunol; 2017 Aug; 38(8):542-557. PubMed ID: 28579323 [TBL] [Abstract][Full Text] [Related]
12. Interferon-omega: Current status in clinical applications. Li SF; Zhao FR; Shao JJ; Xie YL; Chang HY; Zhang YG Int Immunopharmacol; 2017 Nov; 52():253-260. PubMed ID: 28957693 [TBL] [Abstract][Full Text] [Related]
13. [Pathological consequences of excess of interferon in vivo]. Lebon P; Crow YJ; Casanova JL; Gresser I Med Sci (Paris); 2019 Mar; 35(3):232-235. PubMed ID: 30931907 [TBL] [Abstract][Full Text] [Related]
14. [Interferon response: with great power comes great responsibility]. Maarifi G; Smith N; Nisole S Med Sci (Paris); 2020 Mar; 36(3):206-209. PubMed ID: 32228834 [No Abstract] [Full Text] [Related]
15. The Goldilocks Zone of Type I IFNs: Lessons from Human Genetics. Taft J; Bogunovic D J Immunol; 2018 Dec; 201(12):3479-3485. PubMed ID: 30530500 [TBL] [Abstract][Full Text] [Related]
16. Type I interferons in systemic autoimmunity. Sozzani S; Bosisio D; Scarsi M; Tincani A Autoimmunity; 2010 Apr; 43(3):196-203. PubMed ID: 20298124 [TBL] [Abstract][Full Text] [Related]
17. Interferons and immune reactivity. Hooks JJ; Detrick-Hooks B; Levinson AI J Am Vet Med Assoc; 1982 Nov; 181(10):1111-4. PubMed ID: 6184354 [No Abstract] [Full Text] [Related]
18. Type I interferons as immunoregulatory molecules; implications for therapy in experimental autoimmune uveoretinitis. Mizuguchi J; Takeuchi M; Usui M Arch Immunol Ther Exp (Warsz); 2002; 50(4):243-54. PubMed ID: 12371620 [TBL] [Abstract][Full Text] [Related]